TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33401235

Group type: COMPARATOR
Intervention: Obese at randomization
Number of subjects: 8381

Group type: EXPERIMENTAL
Intervention: Weight loss ≥5.0% at 2 years after randomization
Number of subjects: 8381
Study: 35248286

Group type: EXPERIMENTAL
Intervention: Action observation training (experimental group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional physical training + nature pictures (sham group)
Number of subjects: 14
Study: 33418053

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergy immunotherapy (3-year course)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 58
Study: 32270185

Group type: EXPERIMENTAL
Intervention: Improved gait speed
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Improved 6-minute walk distance (6MWD)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no change/a decline in gait speed or 6MWD)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Emergency department visits and hospitalizations
Number of subjects: 303
Study: 33907788

Group type: EXPERIMENTAL
Intervention: Vascularized free fibular bone flap repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non‐vascularized iliac bone graft
Number of subjects: 80
Study: 33181675

Group type: EXPERIMENTAL
Intervention: Smartphone education
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 36449275

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4131

Group type: EXPERIMENTAL
Intervention: Patient nudge
Number of subjects: 4131

Group type: EXPERIMENTAL
Intervention: Clinician nudge
Number of subjects: 4131

Group type: EXPERIMENTAL
Intervention: Combined nudge
Number of subjects: 4131
Study: 33106286

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Brodalumab (both doses)
Number of subjects: 962
Study: 36305424

Group type: EXPERIMENTAL
Intervention: GAN2D
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: GAN3D
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: SCT images (both GAN2D and GAN3D)
Number of subjects: 206
Study: 33441350

Group type: EXPERIMENTAL
Intervention: D-mannose powder daily for 6 months
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo powder daily for 6 months
Number of subjects: 508
Study: 35953331

Group type: EXPERIMENTAL
Intervention: FRIL (20 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CTB-ACE2 (0.925 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CTB-ACE2 gum powder
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FRIL (50-100 ng)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FRIL gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: CTB-ACE2/placebo gum
Number of subjects: 20
Study: 33181049

Group type: EXPERIMENTAL
Intervention: Brexanolone (BRX)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 209
Study: 34189032

Group type: EXPERIMENTAL
Intervention: Warm acupuncture with silver needle (SvN) at above 43°C
Number of subjects: 159

Group type: COMPARATOR
Intervention: Warm acupuncture with stainless steel needle (SSN) at above 40°C
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Warm acupuncture with silver needle (SvN)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Warm acupuncture with stainless steel needle (SSN)
Number of subjects: 159
Study: 34256319

Group type: EXPERIMENTAL
Intervention: Dose-escalated intensity-modulated radiotherapy (DE-IMRT)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard dose intensity-modulated radiotherapy (ST-IMRT)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: DE-IMRT
Number of subjects: 276

Group type: COMPARATOR
Intervention: ST-IMRT
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: DE-IMRT and ST-IMRT
Number of subjects: 276
Study: 34843302

Group type: EXPERIMENTAL
Intervention: Social connectedness intervention
Number of subjects: 416

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 416

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 416
Study: 35802773

Group type: EXPERIMENTAL
Intervention: depression label
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: clinical psychologist recommendation
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: burnout label
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: mind coach recommendation
Number of subjects: 676

Group type: COMPARATOR
Intervention: no label (control)
Number of subjects: 676
Study: 34765049

Group type: EXPERIMENTAL
Intervention: Obese and T2DM (OD) group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Healthy and lean (HL) group
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 280
Study: 34002559

Group type: EXPERIMENTAL
Intervention: Acupuncture (filiform needling and tongue picking acupuncture)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment and swallowing function rehabilitation training (Control)
Number of subjects: 56
Study: 32149745

Group type: EXPERIMENTAL
Intervention: Cervical arthrodesis with plate fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cervical arthroplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-grade ALOD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-grade ALOD
Number of subjects: 40
Study: 35113861

Group type: EXPERIMENTAL
Intervention: Youth peer mentors (YPMs) trained and hired by Project YES!
Number of subjects: 276
Study: 33308810

Group type: EXPERIMENTAL
Intervention: High-velocity, low-load resistance exercise once weekly (HVLL1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise once weekly (LVHL1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-velocity, low-load resistance exercise twice weekly (HVLL2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise twice weekly (LVHL2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-velocity, high-load resistance exercise (LVHL)
Number of subjects: 40
Study: 36039547

Group type: EXPERIMENTAL
Intervention: Group assertive training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 34428360

Group type: EXPERIMENTAL
Intervention: Telehealth CBT‐I
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: In-person CBT‐I
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study: 35639792

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (400,000 IU)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard-dose cholecalciferol (50,000 IU)
Number of subjects: 254
Study: 34108081

Group type: EXPERIMENTAL
Intervention: Aminoglycosides administered in a predialysis schedule
Number of subjects: 206

Group type: COMPARATOR
Intervention: Aminoglycosides administered in a postdialysis schedule
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Predialysis schedule
Number of subjects: 206

Group type: COMPARATOR
Intervention: Postdialysis schedule
Number of subjects: 206
Study: 33225600

Group type: EXPERIMENTAL
Intervention: Patient-reported pain management
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Administration of pain management 'other' than analgesia
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Administration of oral analgesia
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Administration of 'any' analgesia
Number of subjects: 655
Study: 32558298

Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (no colchicine prophylaxis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colchicine prophylaxis (in Australia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in Australia)
Number of subjects: 0
Study: 37744071

Group type: EXPERIMENTAL
Intervention: Experimental PPE (short-sleeved gowns with hand and arm hygiene)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control PPE (long-sleeved gowns)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Experimental PPE
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control PPE
Number of subjects: 85
Study: 33309574

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 35001885

Group type: EXPERIMENTAL
Intervention: Autoimmune disorders (AD)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: MTHFR polymorphisms
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: AD + MTHFR polymorphisms
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in AD
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in MTHFR
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Pre-Prenatal Screening Period fetal losses (CP + BO + gw ≤ 10 fetal losses + EP + TD) in AD + MTHFR
Number of subjects: 243

Group type: COMPARATOR
Intervention: Gravidity ⩽ 4
Number of subjects: 243
Study: 32949500

Group type: EXPERIMENTAL
Intervention: Intravesical Pyo bacteriophage (Pyophage; 20 mL)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intravesical placebo solution (20 mL)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Systemically applied antibiotics
Number of subjects: 113
Study: 35803754

Group type: EXPERIMENTAL
Intervention: Bilateral single‐injection erector spinae plane block (ESPB) with ropivacaine 0.5%, 15 ml on each side
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bilateral single‐injection erector spinae plane block (ESPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient‐controlled intravenous analgesia
Number of subjects: 50
Study: 33966019

Group type: COMPARATOR
Intervention: Saline colloid (6% hydroxyethyl starch 130/0.4 in 0.9% NaCl)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Balanced colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution)
Number of subjects: 88
Study: 35287561

Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 10
Study: 32969548

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT) administered on the tumour bed and pelvis within 6 months of RP.
Number of subjects: 187
Study: 32697031

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT-T)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard cognitive-behavioural therapy (20 sessions)
Number of subjects: 193
Study: 34461038

Group type: EXPERIMENTAL
Intervention: Spore-forming probiotics
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 32826769

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% once-daily
Number of subjects: 839

Group type: COMPARATOR
Intervention: Timolol 0.5% twice-daily
Number of subjects: 839
Study: 34035106

Group type: EXPERIMENTAL
Intervention: Bougie
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Endotracheal tube with stylet
Number of subjects: 1106
Study: 33389912

Group type: EXPERIMENTAL
Intervention: L-PRF application in extraction socket
Number of subjects: 22

Group type: COMPARATOR
Intervention: No material (control) in contralateral socket
Number of subjects: 22
Study: 34363816

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 33577770

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care (with masked CGM)
Number of subjects: 182
Study: 33141262

Group type: EXPERIMENTAL
Intervention: BREATHLESSALL protocol (breathlessness sensory intensity, breathlessness unpleasantness, work/effort of breathing, unsatisfied inspiration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SI+UN protocol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SI alone protocol
Number of subjects: 15
Study: 36162522

Group type: EXPERIMENTAL
Intervention: 4-week cardiac rehabilitation program
Number of subjects: 41
Study: 33740347

Group type: EXPERIMENTAL
Intervention: Transverse puncture method
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vertical puncture method
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 32370061

Group type: EXPERIMENTAL
Intervention: TB NecP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TB TP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TB EOL
Number of subjects: 20

Group type: COMPARATOR
Intervention: RG
Number of subjects: 20
Study: 34915492

Group type: EXPERIMENTAL
Intervention: Cetuximab, 5-fluorouracil, cisplatin, and Docetaxel (D)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cetuximab, 5-fluorouracil, and cisplatin (C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both treatment arms (with and without Docetaxel)
Number of subjects: 180
Study: 34116249

Group type: EXPERIMENTAL
Intervention: G2 - 35% carbamide peroxide (CP) and violet LED
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G4 - 35% hydrogen peroxide (HP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: G1 - violet LED
Number of subjects: 20

Group type: COMPARATOR
Intervention: G3 - only CP 35%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 20
Study: 32725972

Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cystectomy (RARC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 110
Study: 35404709

Group type: EXPERIMENTAL
Intervention: Calisthenic exercise program via telerehabilitation
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group (no formal exercise training)
Number of subjects: 255
Study: 89120227

Group type: EXPERIMENTAL
Intervention: Oral testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 36442498

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Number of subjects: 27882
Study: 33591006

Group type: EXPERIMENTAL
Intervention: EA‐230 (90 mg/kg/hr)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 34779583

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 100 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 250 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 750 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 1000 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg single dose (fed condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) 500 mg single dose (fasting condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone) up to 1000 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LYT‐100 (deupirfenidone)
Number of subjects: 0
Study: 35390321

Group type: EXPERIMENTAL
Intervention: Aggressive warming to a target core temperature of 37°C
Number of subjects: 5013

Group type: COMPARATOR
Intervention: Routine thermal management to a target of 35.5°C
Number of subjects: 5013

Group type: EXPERIMENTAL
Intervention: Aggressive warming
Number of subjects: 5013

Group type: COMPARATOR
Intervention: Routine thermal management
Number of subjects: 5013
Study: 33781703

Group type: EXPERIMENTAL
Intervention: iTBS-γ tACS
Number of subjects: 40

Group type: COMPARATOR
Intervention: iTBS-sham tACS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: γ-tACS alone
Number of subjects: 40
Study: 36409753

Group type: EXPERIMENTAL
Intervention: Home-based exercise utilizing a balance disc and smartphone inclinometer application
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 32
Study: 32193992

Group type: EXPERIMENTAL
Intervention: Treatment with a specific intervention (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Threshold linear mixed model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broyden‐Fletcher‐Goldfarb‐Shanno algorithm
Number of subjects: 0
Study: 34840031

Group type: EXPERIMENTAL
Intervention: Standard treatment + AFO-202 beta glucan (n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standard treatment + combination of AFO-202 and N-163 beta glucans (n=8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard treatment (control group, n=8)
Number of subjects: 24
Study: 32831151

Group type: EXPERIMENTAL
Intervention: Shenfu injection (100 ml, twice a day for 7 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline (identical volume, twice a day for 7 days)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Shenfu injection
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study: 34929690

Group type: EXPERIMENTAL
Intervention: Goal-directed care bundle (early intensive blood pressure lowering, glycaemic control, treatment of pyrexia, and reversal of anticoagulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 33277289

Group type: EXPERIMENTAL
Intervention: Compression garment on top of usual care (information and exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (information and exercises)
Number of subjects: 0
Study: 36202236

Group type: COMPARATOR
Intervention: Standard message group
Number of subjects: 1235

Group type: COMPARATOR
Intervention: COVID-19 vaccine message group
Number of subjects: 1235
Study: 34459398

Group type: EXPERIMENTAL
Intervention: APOE+ PRS
Number of subjects: 6244

Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein (protein PRS APOE‐)
Number of subjects: 6244

Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor‐binding protein 2 (AD APOE‐ PRS)
Number of subjects: 6244

Group type: COMPARATOR
Intervention: Bi-directional MR for five proteins
Number of subjects: 6244
Study: 32998649

Group type: EXPERIMENTAL
Intervention: Mobile phone call intervention delivered by nurses (up to 16 calls, mean duration = 12 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile phone call intervention delivered by nurses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study: 35830313

Group type: EXPERIMENTAL
Intervention: Vestibular incision subperiosteal tunneling access (VISTA) with acellular dermal matrix (ADM) grafts
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sulcular tunnel access (STA) with acellular dermal matrix (ADM) grafts
Number of subjects: 9
Study: 33039390

Group type: EXPERIMENTAL
Intervention: Surgical treatment for pelvic organ prolapse
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Anatomic failure
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Subjective failure
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Retreatment for pelvic organ prolapse
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Transition between success and failure
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Quality-adjusted life years
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Pelvic Organ Prolapse Distress Inventory and Short-Form Six-Dimension health index scores
Number of subjects: 1250
Study: 33168204

Group type: EXPERIMENTAL
Intervention: Classroom-based intervention targeting self-regulation and healthy food liking through mindfulness and games
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 36163989

Group type: EXPERIMENTAL
Intervention: PAC 200mg BID
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: PAC 400mg QD
Number of subjects: 308

Group type: COMPARATOR
Intervention: BAT
Number of subjects: 308
Study: 34798867

Group type: EXPERIMENTAL
Intervention: MRI-based radiomics signature for well-differentiated TSCC
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: MRI-based radiomics signature for poorly differentiated TSCC
Number of subjects: 127
Study: 34340170

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 34028358

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (14 weeks, therapist-guided)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 239
Study: 32985230

Group type: EXPERIMENTAL
Intervention: Caregiver Speaks intervention (photo‐elicitation storytelling via a privately facilitated Facebook group)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Usual hospice care (control group)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Caregiver Speaks intervention
Number of subjects: 468
Study: 32073956

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice a day
Number of subjects: 266

Group type: COMPARATOR
Intervention: Nonplatinum chemotherapy (physician's choice: pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Nonplatinum chemotherapy (physician's choice)
Number of subjects: 266
Study: 33754375

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 75 to 300mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300mg
Number of subjects: 33
Study: 32338459

Group type: EXPERIMENTAL
Intervention: 150 mg generic dabigatran etexilate capsule (test drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial dabigatran etexilate capsule (Pradaxa® , reference drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference drugs
Number of subjects: 0
Study: 34820856

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Leukoreduced RBC transfusions
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: >20 cc/kg volume of leukoreduced RBC transfusions
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: ≥3 leukoreduced RBC transfusions
Number of subjects: 637
Study: 33637477

Group type: EXPERIMENTAL
Intervention: MSPEs for Black and Hispanic/Latinx applicants
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MSPEs overall
Number of subjects: 339